Kura Oncology annual debt-to-equity ratio
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kura Oncology Debt-to-Equity Ratio Growth & History (KURA)
Kura Oncology's debt-to-equity ratio was 0.12 for fiscal 2025.
View full Kura Oncology company overviewKura Oncology annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.12 | 0.08 | +192.84% |
| 2024 | 2024-12-31 | 0.04 | −0.00 | −7.34% |
| 2023 | 2023-12-31 | 0.04 | 0.01 | +29.75% |
| 2022 | 2022-12-31 | 0.03 | 0.02 | +145.89% |
| 2021 | 2021-12-31 | 0.01 | −0.01 | −44.55% |
| 2020 | 2020-12-31 | 0.02 | −0.01 | −31.36% |
| 2019 | 2019-12-31 | 0.04 | −0.01 | −23.47% |
| 2018 | 2018-12-31 | 0.05 | −0.04 | −47.58% |
| 2017 | 2017-12-31 | 0.09 | −0.04 | −30.98% |
| 2016 | 2016-12-31 | 0.13 | — | — |
Kura Oncology quarterly debt-to-equity ratio
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.50 | 0.44 | +692.14% |
| Q1 2026 | 2026-03-31 | 0.22 | 0.17 | +323.63% |
| Q4 2025 | 2025-12-31 | 0.12 | 0.08 | +192.84% |
| Q3 2025 | 2025-09-30 | 0.08 | 0.04 | +104.53% |
| Q2 2025 | 2025-06-30 | 0.06 | 0.03 | +77.55% |
| Q1 2025 | 2025-03-31 | 0.05 | 0.02 | +58.08% |
| Q4 2024 | 2024-12-31 | 0.04 | −0.00 | −7.34% |
| Q3 2024 | 2024-09-30 | 0.04 | −0.00 | −3.17% |
| Q2 2024 | 2024-06-30 | 0.04 | 0.01 | +26.52% |
| Q1 2024 | 2024-03-31 | 0.03 | −0.00 | −1.94% |
| Q4 2023 | 2023-12-31 | 0.04 | 0.01 | +29.75% |
| Q3 2023 | 2023-09-30 | 0.04 | 0.03 | +215.86% |
| Q2 2023 | 2023-06-30 | 0.03 | 0.02 | +116.48% |
| Q1 2023 | 2023-03-31 | 0.03 | 0.02 | +155.36% |
| Q4 2022 | 2022-12-31 | 0.03 | 0.02 | +145.89% |
| Q3 2022 | 2022-09-30 | 0.01 | −0.00 | −6.86% |
| Q2 2022 | 2022-06-30 | 0.01 | 0.00 | +8.69% |
| Q1 2022 | 2022-03-31 | 0.01 | −0.01 | −43.02% |
| Q4 2021 | 2021-12-31 | 0.01 | −0.01 | −44.55% |
| Q3 2021 | 2021-09-30 | 0.01 | −0.04 | −72.63% |
| Q2 2021 | 2021-06-30 | 0.01 | −0.04 | −74.53% |
| Q1 2021 | 2021-03-31 | 0.02 | −0.02 | −50.76% |
| Q4 2020 | 2020-12-31 | 0.02 | −0.01 | −31.36% |
| Q3 2020 | 2020-09-30 | 0.05 | 0.02 | +49.17% |
| Q2 2020 | 2020-06-30 | 0.05 | 0.01 | +46.06% |
| Q1 2020 | 2020-03-31 | 0.05 | −0.01 | −11.68% |
| Q4 2019 | 2019-12-31 | 0.04 | −0.01 | −23.47% |
| Q3 2019 | 2019-09-30 | 0.03 | −0.00 | −5.98% |
| Q2 2019 | 2019-06-30 | 0.03 | −0.03 | −47.68% |
| Q1 2019 | 2019-03-31 | 0.05 | −0.00 | −5.56% |
| Q4 2018 | 2018-12-31 | 0.05 | −0.04 | −47.58% |
| Q3 2018 | 2018-09-30 | 0.04 | −0.04 | −54.54% |
| Q2 2018 | 2018-06-30 | 0.06 | −0.11 | −63.25% |
| Q1 2018 | 2018-03-31 | 0.06 | −0.09 | −60.75% |
| Q4 2017 | 2017-12-31 | 0.09 | −0.04 | −30.98% |
| Q3 2017 | 2017-09-30 | 0.08 | −0.04 | −31.22% |
| Q2 2017 | 2017-06-30 | 0.17 | 0.06 | +61.90% |
| Q1 2017 | 2017-03-31 | 0.15 | — | — |
| Q4 2016 | 2016-12-31 | 0.13 | — | — |
| Q3 2016 | 2016-09-30 | 0.11 | — | — |
| Q2 2016 | 2016-06-30 | 0.10 | — | — |
Kura Oncology debt-to-equity ratio trends
Over the last five fiscal years, Kura Oncology's debt-to-equity ratio increased from 0.02 to 0.12, a change of 0.09. The latest reported quarter, Q2 2026, shows 0.50.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kura Oncology source filings ↗